Making Sense of Biosimilars

Friday, February 24, 2017, 11:33 AM - Saturday, February 24, 2018, 12:33 PM


IU Health Bloomington Noon Conference

1. Define biosimilars and contrast them from reference product and generic drugs.
2. Discuss the history of biologic agents.
3. Explain how biosimilars are approved by the FDA.
4. Identify common concern with the use of biosimilar agents.
5. Recognize economic and clinical impacts of biosimilars.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Indiana University School of Medicine and IU Health Physicians. Indiana University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Indiana University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

For questions about accessibility or to request accommodations please contact the CME office at 317-274-0104 or [email protected]. One week advance notice will allow us to provide seamless access. Please ensure to specify the accommodations you need in order to participate.

AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance (1.00 hours)

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by the Indiana University School of Medicine (IUSM) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

The planning committee and those in a position to control the content of this activity have disclosed no relevant financial relationships.